Journal of Allergy and Clinical Immunology-In Practice最新文献

{"title":"Serum sickness-like reactions clinical characteristics and management: A systematic review.","authors":"Roy Khalaf, UYeong Choi, Connor Prosty, Moshe Ben-Shoshan","doi":"10.1016/j.jaip.2025.02.027","DOIUrl":"https://doi.org/10.1016/j.jaip.2025.02.027","url":null,"abstract":"<p><strong>Background: </strong>Serum sickness-like reaction (SSLR) is an adverse reaction mainly to drugs/infectious agents/ vaccines, characterized by the presence of rash, arthralgia/arthritis and occasionally fever.</p><p><strong>Objective: </strong>This systematic review aimed to analyze the clinical characteristics, implicated agents, symptomatology, and management of SSLR.</p><p><strong>Methods: </strong>A systematic review was conducted following PRISMA guidelines. Case reports and case series were included due to the paucity of data in the literature on SSLR. A comprehensive search of Embase and MedLine was performed. Data extracted included age, comorbidities, medication exposure, time to reaction, symptoms, diagnostic criteria, and treatment modalities. Descriptive statistics were employed to summarize the data. Chi Square test was used to compare categorical variables between adults and children.</p><p><strong>Results: </strong>Forty-four studies comprising 468 patients were included. Antibiotics were more associated with SSLR in children than in adults (P<0.01). Beta-lactam antibiotics, particularly amoxicillin (72.1%), were the leading implicated agents. Dermatological manifestations, primarily maculopapular rashes, were present in 100.0% of cases, while joint symptoms occurred in 78.7%. Corticosteroids were effective in resolving symptoms in most cases.</p><p><strong>Conclusion: </strong>SSLR presents diagnostic challenges due to overlapping symptoms with other drug reactions. Beta-lactams are the most common implicated agents, particularly in pediatric populations. Systemic corticosteroids may provide relief, but standardized guidelines for diagnosis and management are needed. Further research is essential to clarify the pathophysiology and optimize treatment strategies for SSLR.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Clinical Approach to Chronic Cough","authors":"","doi":"10.1016/j.jaip.2025.01.026","DOIUrl":"10.1016/j.jaip.2025.01.026","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 3","pages":"Pages 467-468"},"PeriodicalIF":8.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143549080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unilateral Chronic Rhinosinusitis as a Presenting Sign of a Maxillary Dentigerous Cyst","authors":"Brent T. Griffin MD ,&nbsp;Somsak Sittitavornwong DDS, DMD ,&nbsp;Yedeh Ying MD, DMD ,&nbsp;Do-Yeon Cho MD ,&nbsp;Miranda L. Curtiss MD, PhD","doi":"10.1016/j.jaip.2024.12.006","DOIUrl":"10.1016/j.jaip.2024.12.006","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 3","pages":"Pages 685-686"},"PeriodicalIF":8.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143549237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of rheumatoid arthritis in patients with asthma: A case series","authors":"Richard P. Ramonell MD ,&nbsp;Patricia Choi MD ,&nbsp;Marc C. Gauthier MD ,&nbsp;Merritt L. Fajt MD ,&nbsp;Anuradha Ray PhD ,&nbsp;Sally E. Wenzel MD","doi":"10.1016/j.jaip.2024.12.015","DOIUrl":"10.1016/j.jaip.2024.12.015","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 3","pages":"Pages 692-694.e2"},"PeriodicalIF":8.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national database analysis","authors":"David Garate BS ,&nbsp;Christopher J. Thang BS ,&nbsp;Crystal T. Chang BS ,&nbsp;Shayan Owji MD ,&nbsp;Trevor L. Murphy BS ,&nbsp;George Golovko PhD ,&nbsp;Joel Correa Da Rosa PhD ,&nbsp;Emma Guttman-Yassky MD, PhD ,&nbsp;Michael G. Wilkerson MD ,&nbsp;Nicholas Gulati MD, PhD","doi":"10.1016/j.jaip.2024.11.015","DOIUrl":"10.1016/j.jaip.2024.11.015","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 3","pages":"Pages 698-701.e1"},"PeriodicalIF":8.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nonpharmacological Approaches to Chronic Cough","authors":"Anne E. Vertigan PhD ,&nbsp;Jemma Haines BSc (Hons)","doi":"10.1016/j.jaip.2024.12.012","DOIUrl":"10.1016/j.jaip.2024.12.012","url":null,"abstract":"<div><div>Although cough is a protective reflex, it can occur in the absence of any physical need to clear the airway. In chronic cough, cough can be triggered by innocuous stimuli and persist despite medical treatment. Nonpharmacological interventions such as cough control therapy, provided by speech pathologists, have gained popularity in recent years. Intervention targets refractory or unexplained chronic cough, and efficacy has been studied in randomized controlled trials. Key elements of cough control therapy include education, anticipation, and control of the urge to cough, reducing laryngeal irritation and psychoeducational counseling. Our understanding of the mechanisms behind the success of nonpharmacological treatment is developing. It is likely the mechanisms of action are multifactorial across peripheral, central, and higher cortical regions. Nonpharmacological cough control therapy interventions are now included in international cough guidelines. However, approach to service delivery is not standardized and varies between regions and countries.</div></div>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 3","pages":"Pages 480-488"},"PeriodicalIF":8.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Mast Cell Disease in Women: A Case Study of Delayed Diagnosis of Systemic Mastocytosis","authors":"Vishaka R. Hatcher MD ,&nbsp;Veronica C. Alix MD ,&nbsp;Tasha S. Hellu DO ,&nbsp;Meredith M. Schuldt MD ,&nbsp;Karla E. Adams MD, FAAAAI","doi":"10.1016/j.jaip.2025.01.019","DOIUrl":"10.1016/j.jaip.2025.01.019","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 3","pages":"Pages 680-682"},"PeriodicalIF":8.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Long-Term Prophylactic and On-Demand Therapies for Hereditary Angioedema","authors":"Ashley Y. Wu MD ,&nbsp;Aleena Banerji MD","doi":"10.1016/j.jaip.2025.01.021","DOIUrl":"10.1016/j.jaip.2025.01.021","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 3","pages":"Pages 715-717"},"PeriodicalIF":8.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Clinical Approach to Chronic Cough","authors":"Imran Satia MD ,&nbsp;Wafa Hassan MD ,&nbsp;Lorcan McGarvey MD ,&nbsp;Surinder S. Birring MD","doi":"10.1016/j.jaip.2024.11.004","DOIUrl":"10.1016/j.jaip.2024.11.004","url":null,"abstract":"<div><div>Chronic cough remains a significant clinical challenge, affecting approximately 10% of the population and leading to significant impairment in psychological, social, and physical quality of life. In recent years, efforts have intensified to elucidate the mechanisms underlying chronic cough and to focus on investigating and treating refractory chronic cough (RCC). A “treatable trait” approach, which focuses on identifying and addressing the specific associated causes of chronic cough, has gained traction. In some patients, RCC is likely driven by a neuropathic mechanism due to dysregulation of the neuronal pathways involved in the cough reflex, often clinically described as cough hypersensitivity syndrome. Although the initial treatment of underlying conditions remains central to managing treatable traits, the therapeutic options for RCC have expanded to include targeting cough hypersensitivity. First-line treatments now include neuromodulators and speech therapy with one P2X3 receptor antagonist (gefapixant) recently licensed in the European Union, United Kingdom, and Japan. Despite these advances, patient responses remain variable, underscoring the ongoing need for research into the pathophysiology and treatment of RCC. This article reviews current investigations and management options in treating chronic cough and RCC.</div></div>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 3","pages":"Pages 454-466"},"PeriodicalIF":8.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness of Oral Immunotherapy for Egg Allergy According to Age of Therapy Commencement","authors":"Melanie Lloyd PhD ,&nbsp;Jedidiah I. Morton PhD ,&nbsp;Rachel L. Peters PhD ,&nbsp;Paxton Loke PhD ,&nbsp;Sarah Ashley PhD ,&nbsp;Marcus S. Shaker MD, MS ,&nbsp;Matthew Greenhawt MD, MBA, MSc ,&nbsp;Zanfina Ademi PhD ,&nbsp;Mimi L.K. Tang PhD","doi":"10.1016/j.jaip.2024.12.005","DOIUrl":"10.1016/j.jaip.2024.12.005","url":null,"abstract":"<div><h3>Background</h3><div>Egg oral immunotherapy (OIT) can induce desensitization or remission of egg allergy in children.</div></div><div><h3>Objective</h3><div>To determine the cost-effectiveness of OIT for raw egg allergy in school-age children compared with egg avoidance, and the most cost-effective age at which to commence treatment.</div></div><div><h3>Methods</h3><div>A decision-analytic Markov model estimated the health and cost outcomes of 1,000 children aged 4 years with egg allergy, comparing different ages of OIT commencement (ages 4-12, inclusive) versus ongoing egg avoidance. Years lived with egg allergy, egg tolerance or remission (natural and OIT-induced), and desensitization to egg were captured, with rates of allergic reactions and utility values assigned to each health state. Treatment effects were derived from published randomized clinical trials and meta-analyses. The main outcome was the incremental cost-effectiveness ratio (ICER) from the Australian health care payer perspective (costs in Australian dollars per quality-adjusted life-year [QALY] gained), with a 20-year time horizon, 5% annual discounting, and an AU $50,000/QALY willingness-to-pay (WTP) threshold.</div></div><div><h3>Results</h3><div>Without OIT, 858 children attained natural resolution before age 24. Under conservative assumptions, with OIT-induced remission set at zero and 84% achieving desensitization, ICERs were below the WTP threshold for treatment commencement at age 8 or older, with the smallest ICER observed at age 12 (AU $43,233/QALY; 95% CI, 32,025-73,350). However, the cost-effectiveness of OIT was achieved at all ages (ICER less than the WTP threshold) when OIT-induced remission increased to ∼40% of treated children.</div></div><div><h3>Conclusions</h3><div>Based on current published evidence, the cost-effectiveness of egg OIT improves with increased age of treatment commencement. Cost-effectiveness increases when the proportion of children achieving OIT-induced remission increases.</div></div>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 3","pages":"Pages 619-629"},"PeriodicalIF":8.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142830833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}